Year archive

Ascletis Pharma Inc. — 2021 filings

All 160 regulatory filings released by Ascletis Pharma Inc. (1672) in 2021, sourced directly from the official regulator.

160 Filings

2021 Period

2021 filings (160)

Filing	Released	Lang
FURTHER DELAY IN DESPATCH OF CIRCULAR IN RESPECT OF VERY SUBSTANTIAL DISPOSAL AND VERY SUBSTANTIAL ACQUISITION IN RELATION TO LAND RESUMPTION Regulatory Filings	2021-12-31	English
Next Day Disclosure Return Regulatory Filings	2021-12-31	English
Next Day Disclosure Return Regulatory Filings	2021-12-30	English
Next Day Disclosure Return Regulatory Filings	2021-12-29	English
Next Day Disclosure Return Regulatory Filings	2021-12-28	English
Next Day Disclosure Return Regulatory Filings	2021-12-24	English
Next Day Disclosure Return Regulatory Filings	2021-12-23	English
Next Day Disclosure Return Regulatory Filings	2021-12-22	English
Next Day Disclosure Return Regulatory Filings	2021-12-21	English
Next Day Disclosure Return Regulatory Filings	2021-12-20	English
Next Day Disclosure Return Regulatory Filings	2021-12-17	English
Next Day Disclosure Return Regulatory Filings	2021-12-16	English
Next Day Disclosure Return Regulatory Filings	2021-12-15	English
Next Day Disclosure Return Regulatory Filings	2021-12-14	English
Next Day Disclosure Return Regulatory Filings	2021-12-13	English
Next Day Disclosure Return Regulatory Filings	2021-12-10	English
Next Day Disclosure Return Regulatory Filings	2021-12-09	English
Next Day Disclosure Return Regulatory Filings	2021-12-08	English
Next Day Disclosure Return Regulatory Filings	2021-12-07	English
Next Day Disclosure Return Regulatory Filings	2021-12-06	English
Next Day Disclosure Return Regulatory Filings	2021-12-03	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2021 Regulatory Filings	2021-12-03	English
EXCHANGE NOTICE - RESUMPTION OF TRADING Regulatory Filings	2021-12-03	English
ANNOUNCEMENT - INSIDE INFORMATION - INCLUSION IN NEW CATALOGUE OF CHINA NATIONAL REIMBURSEMENT DRUG LIST (NRDL) OF ASCLEVIR/GANOVO REGIMEN, AN ALL-ORAL DIRECT ANTI-HCV THERAPY AND RESUMPTION OF Regulatory Filings	2021-12-03	English
TRADING HALT Regulatory Filings	2021-12-03	English
EXCHANGE NOTICE - TRADING HALT Regulatory Filings	2021-12-03	English
Next Day Disclosure Return Regulatory Filings	2021-12-02	English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 November 2021 Regulatory Filings	2021-12-01	English
Next Day Disclosure Return Regulatory Filings	2021-12-01	English
Next Day Disclosure Return Regulatory Filings	2021-11-30	English
Next Day Disclosure Return Regulatory Filings	2021-11-29	English
DELAY IN DESPATCH OF CIRCULAR IN RESPECT OF VERY SUBSTANTIAL DISPOSAL AND VERY SUBSTANTIAL ACQUISITION IN RELATION TO LAND RESUMPTION Regulatory Filings	2021-11-26	English
Next Day Disclosure Return Regulatory Filings	2021-11-26	English
Next Day Disclosure Return Regulatory Filings	2021-11-25	English
Next Day Disclosure Return Regulatory Filings	2021-11-24	English
Next Day Disclosure Return Regulatory Filings	2021-11-23	English
Next Day Disclosure Return Regulatory Filings	2021-11-19	English
Next Day Disclosure Return Regulatory Filings	2021-11-18	English
VOLUNTARY ANNOUNCEMENT - FIRST SUBJECT DOSED IN THE U.S. PHASE I TRIAL FOR ASC43F ONLY HALF A MONTH AFTER IND APPROVAL BY THE U.S. FDA Regulatory Filings	2021-11-18	English
Next Day Disclosure Return Regulatory Filings	2021-11-17	English
Next Day Disclosure Return Regulatory Filings	2021-11-16	English
VOLUNTARY ANNOUNCEMENT - CLINICAL STUDIES OF PD-L1 ANTIBODY ASC22 FOR HBV FUNCTIONAL CURE SELECTED FOR INCLUSION IN THE "BEST OF THE LIVER MEETING'S SUMMARY" BY AASLD REVIEW COMMITTEE Regulatory Filings	2021-11-16	English
Next Day Disclosure Return Regulatory Filings	2021-11-15	English
VOLUNTARY ANNOUNCEMENT - CHINA NMPA APPROVED PHASE II AND III PROTOCOLS OF ASC42, AN FXR AGONIST, FOR TREATMENT OF PRIMARY BILIARY CHOLANGITIS Regulatory Filings	2021-11-15	English
Next Day Disclosure Return Regulatory Filings	2021-11-12	English
Next Day Disclosure Return Regulatory Filings	2021-11-11	English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES APPROVAL OF PHASE II CLINICAL TRIAL OF ASC22 (ENVAFOLIMAB) BY CHINA NMPA FOR IMMUNE RESTORATION/ FUNCTIONAL CURE OF HIV-1 INFECTED PATIENTS Regulatory Filings	2021-11-10	English
Next Day Disclosure Return Regulatory Filings	2021-11-09	English
VOLUNTARY ANNOUNCEMENT - SUSTAINED HEPATITIS B SURFACE ANTIGEN LOSS IN CHRONIC HEPATITIS B PATIENTS WITH SUBCUTANEOUS PD-L1 ANTIBODY ASC22 TREATMENT: INTERIM RESULTS OF PHASE IIb STUDY Regulatory Filings	2021-11-09	English
Next Day Disclosure Return Regulatory Filings	2021-11-08	English
ANNOUNCEMENT - INSIDE INFORMATION - EXCLUSIVE AND WORLDWIDE LICENSE AGREEMENT OUTSIDE GREATER CHINA WITH SUZHOU ALPHAMAB FOR ASC22 (ENVAFOLIMAB) TO TREAT HEPATITIS B AND OTHER VIRAL DISEASES Regulatory Filings	2021-11-08	English
VERY SUBSTANTIAL DISPOSAL AND VERY SUBSTANTIAL ACQUISITION IN RELATION TO LAND RESUMPTION Regulatory Filings	2021-11-05	English
Next Day Disclosure Return Regulatory Filings	2021-11-05	English
Next Day Disclosure Return Regulatory Filings	2021-11-04	English
Next Day Disclosure Return Regulatory Filings	2021-11-03	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2021 Regulatory Filings	2021-11-03	English
Next Day Disclosure Return Regulatory Filings	2021-11-02	English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS Regulatory Filings	2021-11-01	English
CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE OF COMPOSITION OF BOARD COMMITTEES Regulatory Filings	2021-11-01	English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 October 2021 Regulatory Filings	2021-11-01	English
Next Day Disclosure Return Regulatory Filings	2021-11-01	English
VOLUNTARY ANNOUNCEMENT - GANNEX ANNOUNCES U.S. IND APPROVAL OF ASC43F, A FIRST-IN-CLASS DUAL-TARGET FIXED-DOSE COMBINATION FOR NASH Regulatory Filings	2021-11-01	English
Next Day Disclosure Return Regulatory Filings	2021-10-29	English
Next Day Disclosure Return Regulatory Filings	2021-10-28	English
Next Day Disclosure Return Regulatory Filings	2021-10-27	English
Next Day Disclosure Return Regulatory Filings	2021-10-27	English
Next Day Disclosure Return Regulatory Filings	2021-10-26	English
Next Day Disclosure Return Regulatory Filings	2021-10-25	English
Next Day Disclosure Return Regulatory Filings	2021-10-22	English
Next Day Disclosure Return Regulatory Filings	2021-10-21	English
Next Day Disclosure Return Regulatory Filings	2021-10-21	English
Next Day Disclosure Return Regulatory Filings	2021-10-20	English
Next Day Disclosure Return Regulatory Filings	2021-10-19	English
Next Day Disclosure Return Regulatory Filings	2021-10-18	English
Next Day Disclosure Return Regulatory Filings	2021-10-15	English
VOLUNTARY ANNOUNCEMENT - GANNEX ANNOUNCES CLINICAL AND PRECLINICAL DATA OF FOUR NASH PROGRAMS TO BE PRESENTED IN ORAL OR POSTER PRESENTATION AT THE LIVER MEETING 2021 BY AMERICAN ASSOCIATION FOR THE S Regulatory Filings	2021-10-13	English
Next Day Disclosure Return Regulatory Filings	2021-10-12	English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES RESULTS OF THE PHASE IIa TRIAL OF ASC22 (ENVAFOLIMAB) IN PATIENTS WITH CHRONIC HEPATITIS B TO BE PRESENTED IN ORAL PARALLEL SESSION AT THE LIVER MEETING 202 Regulatory Filings	2021-10-12	English
Next Day Disclosure Return Regulatory Filings	2021-10-11	English
VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE AND VOLUME MOVEMENTS Regulatory Filings	2021-10-11	English
VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE AND VOLUME MOVEMENTS Regulatory Filings	2021-10-08	English
Next Day Disclosure Return Regulatory Filings	2021-10-08	English
Next Day Disclosure Return Regulatory Filings	2021-10-07	English
VOLUNTARY ANNOUNCEMENT - PROPOSED SHARE REPURCHASE UNDER THE REPURCHASE MANDATE Regulatory Filings	2021-10-06	English
Next Day Disclosure Return Regulatory Filings	2021-10-04	English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 September 2021 Regulatory Filings	2021-10-04	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2021 Regulatory Filings	2021-09-30	English
GRANT OF SHARE OPTIONS Regulatory Filings	2021-09-30	English
Notification Letter with Request Form to Non-Registered Holders of Shares - Notice of Publication of Interim Report 2021 Regulatory Filings	2021-09-24	English
Interim Report 2021 Regulatory Filings	2021-09-24	English
INTERIM REPORT 2021 Regulatory Filings	2021-09-23	English
VOLUNTARY ANNOUNCEMENT - GANNEX ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE U.S. PHASE I TRIAL OF DRUG-DRUG INTERACTIONS IN HEALTHY SUBJECTS AND PHARMACOKINETICS IN PATIENTS WITH NAFLD FOR ITS THR AGO Regulatory Filings	2021-09-08	English
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT OF THE COMPANY FOR THE YEAR ENDED 31 DECEMBER 2020 Regulatory Filings	2021-09-07	English
Next Day Disclosure Return Regulatory Filings	2021-09-06	English
VOLUNTARY ANNOUNCEMENT - GANNEX ANNOUNCES CLINICAL TRIAL APPLICATION OF ASC42, AN FXR AGONIST, FOR TREATMENT OF PRIMARY BILIARY CHOLANGITIS ACCEPTED BY CHINA NMPA Regulatory Filings	2021-09-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2021 Regulatory Filings	2021-09-03	English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 August 2021 Regulatory Filings	2021-09-01	English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2021 Regulatory Filings	2021-08-26	English
ANNOUNCEMENT OF INTERIM RESULTS 2021 Regulatory Filings	2021-08-26	English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES COMPLETION OF THE BRIDGING STUDY AND INITIATION OF PHASE II TRIAL OF FXR AGONIST ASC42 IN CHINA FOR CHRONIC HEPATITIS B INDICATION Regulatory Filings	2021-08-25	English
VOLUNTARY ANNOUNCEMENT - ASCLETIS' PARTNER SAGIMET DOSED FIRST PATIENT IN FASCINATE-2 PHASE IIB TRIAL IN NASH PATIENTS WITH MODERATE TO ADVANCED FIBROSIS Regulatory Filings	2021-08-16	English
DATE OF BOARD MEETING Regulatory Filings	2021-08-16	English
NOTICE OF BOARD MEETING Regulatory Filings	2021-08-13	English
VOLUNTARY ANNOUNCEMENT - CHINA NMPA APPROVES PHASE II CLINICAL TRIAL OF ASC40 FOR THE TREATMENT OF PATIENTS WITH ACNE Regulatory Filings	2021-08-09	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2021 Regulatory Filings	2021-08-05	English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 July 2021 Regulatory Filings	2021-08-05	English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES COMPLETION OF 149 PATIENT ENROLLMENT AND POSITIVE INTERIM RESULTS OF PHASE IIb CHRONIC HEPATITIS B STUDY IN CHINA FOR ITS SUBCUTANEOUSLY ADMINISTERED PD-L1 Regulatory Filings	2021-07-28	English
ANNOUNCEMENT - INSIDE INFORMATION - CHINA NMPA APPROVES PHASE III CLINICAL TRIAL OF ASC40 COMBINED WITH BEVACIZUMAB FOR TREATMENT OF PATIENTS WITH RECURRENT GLIOBLASTOMA Regulatory Filings	2021-07-22	English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES DOSING OF THE FIRST COHORT OF HEALTHY SUBJECTS IN THE FXR AGONIST ASC42 BRIDGING STUDY FOR CHRONIC HEPATITIS B INDICATION IN CHINA Regulatory Filings	2021-07-13	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2021 Regulatory Filings	2021-07-07	English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 June 2021 Regulatory Filings	2021-07-02	English
GRANT OF SHARE OPTIONS Regulatory Filings	2021-06-30	English
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 29, 2021 Regulatory Filings	2021-06-29	English
POLL RESULTS OF ANNUAL GENERAL MEETING ON 25 JUNE 2021 Regulatory Filings	2021-06-25	English
VOLUNTARY ANNOUNCEMENT - GANNEX ANNOUNCES POSITIVE TOPLINE RESULTS OF THE U.S. PHASE I TRIAL OF NASH DRUG ASC42, AN FXR AGONIST Regulatory Filings	2021-06-16	English
VOLUNTARY ANNOUNCEMENT - ASCLETIS RECEIVED CHINA IND APPROVAL OF ITS FXR AGONIST ASC42 FOR CHRONIC HEPATITIS B INDICATION Regulatory Filings	2021-06-07	English
Next Day Disclosure Return Regulatory Filings	2021-06-03	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2021 Regulatory Filings	2021-06-02	English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 May 2021 Regulatory Filings	2021-06-01	English
Notification Letter to Non-Registered Holders of Shares with Request Form - Notice of Publication of Circular containing Notice of Annual General Meeting Regulatory Filings	2021-05-27	English
Form of Proxy for the 2021 Annual General Meeting Regulatory Filings	2021-05-27	English
Notice of 2021 Annual General Meeting Regulatory Filings	2021-05-27	English
Proposals for General Mandates to Issue Shares and to Repurchase Shares, Re-election of Retiring Directors and Notice of Annual General Meeting Regulatory Filings	2021-05-27	English
VOLUNTARY ANNOUNCEMENT - GANNEX RECEIVED CHINA IND APPROVAL OF ITS FXR AGONIST ASC42 FOR NASH INDICATION Regulatory Filings	2021-05-27	English
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPLICATION OF ASC40 COMBINED WITH BEVACIZUMAB TO TREAT PATIENTS WITH RECURRENT GLIOBLASTOMA ACCEPTED BY CHINA NMPA Regulatory Filings	2021-05-25	English
VOLUNTARY ANNOUNCEMENT - POSITIVE PHASE IIA HBV RESULTS ON SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ASC22 (ENVAFOLIMAB) Regulatory Filings	2021-05-05	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2021 Regulatory Filings	2021-05-04	English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 April 2021 Regulatory Filings	2021-05-03	English
Notification Letter to Non-Registered Holders of Shares with Request Form - Notice of Publication of Annual Report 2020 Regulatory Filings	2021-04-28	English
Annual Report 2020 Regulatory Filings	2021-04-28	English
NOTICE OF ANNUAL GENERAL MEETING Regulatory Filings	2021-04-27	English
GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, RE-ELECTION OF RETIRING DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING Regulatory Filings	2021-04-27	English
Annual Report 2020 Regulatory Filings	2021-04-27	English
FORM OF PROXY FOR ANNUAL GENERAL MEETING (or any adjournment thereof) Regulatory Filings	2021-04-27	English
VOLUNTARY ANNOUNCEMENT - GANNEX ANNOUNCES THE FIRST COHORT DOSED IN A U.S. CLINICAL STUDY WITH THR-BETA AGONIST ASC41 Regulatory Filings	2021-04-14	English
VOLUNTARY ANNOUNCEMENT - FOUR CLINICAL AND PRECLINICAL STUDY ABSTRACTS OF NASH AND HBV ACCEPTED AS POSTER PRESENTATIONS BY THE INTERNATIONAL LIVER CONGRESS 2021 Regulatory Filings	2021-04-12	English
GRANT OF SHARE OPTIONS Regulatory Filings	2021-04-07	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2021 Regulatory Filings	2021-04-07	English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 March 2021 Regulatory Filings	2021-04-07	English
GRANT OF SHARE OPTIONS Regulatory Filings	2021-03-31	English
RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2020 Regulatory Filings	2021-03-30	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020 Regulatory Filings	2021-03-30	English
INSIDE INFORMATION - INVESTMENT ESCALATION IN THE R&D OF CANCER LIPID METABOLISM AND ORAL CHECKPOINT INHIBITORS AND PROPOSED INITIATION OF A PIVOTAL PHASE II TRIAL OF ASC40 IN COMBINATION WITH BEV Regulatory Filings	2021-03-30	English
DATE OF BOARD MEETING Regulatory Filings	2021-03-18	English
NOTICE OF BOARD MEETING Regulatory Filings	2021-03-17	English
VOLUNTARY ANNOUNCEMENT - FASN INHIBITOR ASC40 DEMONSTRATES POSITIVE PHASE II TOPLINE CLINICAL RESULTS FROM CHINA COHORT OF PATIENTS WITH NASH Regulatory Filings	2021-03-09	English
CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG Regulatory Filings	2021-03-08	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2021 Regulatory Filings	2021-03-03	English
Monthly Return of Equity Issuer on movements in Securities for the month ended 28 February 2021 Regulatory Filings	2021-03-02	English
VOLUNTARY ANNOUNCEMENT - GANNEX ANNOUNCES U.S. IND APPROVAL AND INITIATION OF GLOBAL DEVELOPMENT OF THR-BETA AGONIST ASC41 FOR NASH Regulatory Filings	2021-02-25	English
VOLUNTARY ANNOUNCEMENT - GANNEX ANNOUNCES POSITIVE CLINICAL RESULTS IN OVERWEIGHT AND OBESE SUBJECTS FOR ITS THR-BETA AGONIST ASC41 DATA FURTHER CONFIRMED DOSES FOR PHASE II TRIAL IN PATIENTS WITH NAS Regulatory Filings	2021-02-21	English
VOLUNTARY ANNOUNCEMENT - PARTICIPATION IN SAGIMET'S US$80 MILLION IN CROSSOVER FINANCING WITH PREMIUM INVESTORS Regulatory Filings	2021-02-11	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 20201 Regulatory Filings	2021-02-02	English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 January 2021 Regulatory Filings	2021-02-01	English
CHANGE OF REGISTERED OFFICE, PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE IN THE CAYMAN ISLANDS Regulatory Filings	2021-02-01	English
Next Day Disclosure Return Regulatory Filings	2021-01-14	English
VOLUNTARY ANNOUNCEMENT - GANNEX ANNOUNCES POSITIVE PHASE I CLINICAL RESULTS ON ITS THR-BETA AGONIST ASC41 Regulatory Filings	2021-01-12	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2020 Regulatory Filings	2021-01-05	English
VOLUNTARY ANNOUNCEMENT Consultation with Two Government Departments on Land Use Rights Resumption of Zongdi G05701-4 Regulatory Filings	2021-01-04	English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 December 2020 Regulatory Filings	2021-01-04	English

Filings by year

2026 22 filings
2025 159 filings
2024 184 filings
2023 178 filings
2022 127 filings
2021 160 filings
2020 98 filings
2019 74 filings
2018 63 filings
2017 33 filings
2016 31 filings
2015 30 filings
2014 27 filings
2013 29 filings
2012 41 filings
2011 29 filings
2010 27 filings
2009 23 filings
2008 16 filings
2007 23 filings
2006 18 filings
2005 19 filings
2004 18 filings
2003 13 filings
2002 8 filings
2001 7 filings
2000 8 filings
1999 5 filings